Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 1.00 |
| ▸ | SCN4A | P35499 | 4/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.61 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.57 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.57 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.57 |
| ▸ | BRAF | P15056 | 1/20 | 0.56 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LTA4H | P09960 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17279817 | 0.87 | POLB (0.77) | PDPK1SCN4APOLBPTPN11CYP2E1 | |
| SCHEMBL23105893 | 0.82 | PDPK1 (0.68) | PDPK1SCN4APOLBPTPN11CYP2E1 | |
| SCHEMBL3200989 | 0.80 | — | — | |
| SCHEMBL3026361 | 0.80 | SCN4A (1.00) | PDPK1SCN4APOLBPTPN11CYP2E1 | |
| SCHEMBL18235564 | 0.79 | NOTUM (0.71) | PDPK1SCN4APOLBPTPN11CYP2E1 | |
| SCHEMBL3068150 | 0.78 | SCN4A (0.62) | PDPK1SCN4APOLBPTPN11CYP2E1 | |
| SCHEMBL104517 | 0.76 | SCN4A (0.79) | PDPK1SCN4APOLBPTPN11CYP2E1 | |
| SCHEMBL20958709 | 0.76 | CYP2E1 (0.64) | PDPK1SCN4APOLBPTPN11CYP2E1 | |
| SCHEMBL16168729 | 0.76 | POLB (0.63) | PDPK1SCN4APOLBPTPN11CYP2E1 | |
| SCHEMBL482367 | 0.76 | POLB (1.00) | PDPK1SCN4APOLBPTPN11NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119708069-A | Bivalent platinum complex, preparation method and application thereof, and organic photoelectric device | 中国石油化工股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20240131356-A1 | COMBINATION OF INTRACELLULAR AND EXTRACELLULAR PHOTOSENSITIZERS FOR TREATMENT OF BACTERIAL INFECTION | VANDERBILT UNIVERSITY | 2024-04-25 | — | — | US | disclosed |
| WO-2014047330-A1 | NOVEL RAF KINASE INHIBITORS | VERNIER JEAN-MICHEL (US) | 2014-03-27 | — | — | WO | disclosed |
| WO-2010046780-A2 | ANTI VIRAL COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010046780-A2 | ANTI VIRAL COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2010-04-29 | — | — | WO | disclosed |
| CN-1894235-A | N-(4-carbamimidoyl-benzyl) -2-alkoxy-2-heterocyclyl acetamides as inhibitors of the formation of coagulation factors xa, ixa and thrombin induced by factor viia | HOFFMANN LA ROCHE (CH) | 2007-01-10 | — | — | CN | disclosed |
| EP-1706396-A1 | N-(4-CARBAMIMIDOYL-BENZYL)-2-ALKOXY-2-HETEROCYCLYL ACETAMIDES AS INHIBITORS OF THE FORMATION OF COAGULATION FACTORS XA, IXA AND THROMBIN INDUCED BY FACTOR VIIA | F.HOFFMANN-LA ROCHE AG (CH) | 2006-10-04 | — | — | EP | disclosed |
| US-7056932-B2 | Heterocyclyl substituted 1-alkoxy acetic acid amides | HOFFMAN-LA ROCHE INC. (US) | 2006-06-06 | — | — | US | disclosed |
| WO-2005058868-A1 | N-(4-CARBAMIMIDOYL-BENZYL) -2-ALKOXY-2-HETEROCYCLYL ACETAMIDES AS INHIBITORS OF THE FORMATION OF COAGULATION FACTORS XA, IXA AND THROMBIN INDUCED BY FACTOR VIIA | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| US-20050137168-A1 | Heterocyclyl substituted 1-alkoxy acetic acid amides | HOFFMANN-LA ROCHE INC. | 2005-06-23 | — | — | US | disclosed |
| US-6509361-B1 | Inhibit the activity of p38 MAP kinase. Also contemplated by the invention are processes for the preparation of the contemplated compounds and for the use of a contemplated compound in treating a mammalian host having a p38 kinase or | PHARMACIA CORPORATION | 2003-01-21 | — | — | US | disclosed |
| EP-1077971-A1 | 1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. SEARLE & CO. (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058523-A1 | 1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. SEARLE & CO. (US) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137168-A1 | Heterocyclyl substituted 1-alkoxy acetic acid amides | F12, TFPI, F11 | PDPK1 3627/4885SCN4A 2001/4885POLB 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.